For example, it is well established that GLP-1R agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase endogenous GLP-1, reduce infarct size after experimental ischaemia and enhance functional recovery upon reperfusion [8, 19, 20]. The gene discussed is DPP4; the disease is ischemia.